TELA Bio, Inc. announced the approval of inducement grants of restricted stock units covering 14,250 shares of its common stock to five newly-hired employees. The grants were made on January 20, 2026, and will vest in equal annual installments over four years, contingent on continued service with the company. TELA Bio is a medical technology company focused on providing soft-tissue reconstruction solutions that prioritize the patient’s own anatomy. The company aims to optimize clinical outcomes while minimizing exposure to permanent synthetic materials. Forward-looking statements in the press release caution about potential risks and uncertainties.

Read more at GlobeNewswire: TELA Bio Announces Inducement Grants Under Nasdaq Listing